Cutaneous Manifestations of Anthrax in Eastern Anatolia: A Review of 39 Cases

Acta Medica Okayama

Volumn 57, Issue 5, 2003, Pages 235-240

  Irmak, Hasan ^a   Buzgan, Turan ^a   Karahocagil, Mustafa Kasim ^a   Sakarya, Nurten ^a   Akdeniz, Hayrettin ^a   Çaksen, Hüseyin ^a   Demiröz, Pekcan ^a  

^a YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Clinical findings; Cutaneous anthrax; Prognosis; Treatment

Indexed keywords

PENICILLIN G; PROCAINE;

ADOLESCENT; ADULT; AGED; ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL INFECTION; BACTERIUM ISOLATE; CAUSE OF DEATH; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EDEMA; FEMALE; GRAM STAINING; HUMAN; LARYNX EDEMA; MALE; PATIENT; PENICILLIN ALLERGY; PUSTULE; REVIEW; SEPSIS; SKIN DEFECT; SKIN MANIFESTATION; SMEAR; SUPERINFECTION;

ADULT; ANTHRAX; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PENICILLIN G; PENICILLIN G, PROCAINE; PREDNISOLONE; RECONSTRUCTIVE SURGICAL PROCEDURES; SKIN DISEASES, BACTERIAL; TURKEY;

ANIMALIA; ANTHRAX; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 0345446618     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Doganay M: Şarbon; in Infeksiyon Hastaliklari, Topçu AW, Söyletir G and Doganay M eds, 1st Ed, Nobel Tip Kitabevi, İstanbul (1996) pp 799-803.
2. Lew DP: Bacillus anthracis (Anthrax); in Principles and Practice of Infectious Diseases, Mandell GL, Bennett JE and Dolin R eds, 5th Ed, Churchill Livingstone, New York (2000) pp 2215-2220.
3. Brossier F and Mock M: Toxins of Bacillus anthracis. Toxicon (2001) 39: 1747-1755.
4. Bilgehan H: Klinik Mikrobiyoloji (Özel Bakteriyoloji ve Bakteri Enfeksiyonlari). 9th Ed, Fakülteler Kitabevi, İzmir (1996) pp 313-318.
5. Penn CC and Klotz SA: Bacillus anthracis and other aerobic spore formers; in Infectious Diseases, Gorbach SL, Bartlett JG and Blacklow NR eds, 2nd Ed, WB Saunders Co, Philadelphia (1998) pp 1747-1750.
6. Alexeyev OA, Morozov VG, Suzdaltseva TV, Mishukov AS and Steinberg LA: Impaired neutrophil function in the cutaneous form of anthrax. Infection (1994) 22: 281-282.
7. Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD and Vande Woude GF: Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 280: 734-737.
8. Price LB, Hugh-Jones M, Jackson PJ and Keim P: Genetic diversity in the protective antigen gene of Bacillus anthracis. J Bacteriol (1999) 181: 2358-2362.
9. Smego RA Jr, Gebrian B and Desmangels G: Cutaneous manifestations of anthrax in rural Haiti. Clin Infect Dis (1998) 26: 97-102.
10. Swartz MN: Recognition and management of anthrax-an update. N Eng J Med (2001) 345: 1621-1626.
11. La Force FM: Anthrax. Clin Infect Dis (1994) 19: 1009-1014.
12. Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK and Tonat K: Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 281: 1735-1745.
13. Doganay M and Aygen B: Diagnosis: cutaneous anthrax. Clin Infect Dis (1997) 25: 607, 725.
14. Friedlander AM: Anthrax: Clinical features, pathogenesis, and potential biological warfare threat; in Current Clinical Topics in Infectious Diseases. Remington JS and Swartz MN eds, Blackwell Science, Malden, Mass (2000) pp 335-349.
15. Çaksen H, Ataş B, Odabaş D and Irmak H: Anthrax of the eyelid in a Turkish girl. Pediatr Dermatol (2003) 20: 93-94.
16. Kaya A, Taşyaran MA, Özkurt Z and Yilmaz Ş: Şarbon: 68 olgunun deǧerlendirilmesi. Flora (1997) 1: 51-54 (in Turkish).
17. Doganay M, Kökkaya A and Hah MM: 35 şarbon olgusunun deǧ erlendirimi. Mikrobiyol Bült (1983) 17: 1-10.
18. Christie AB: Infectious Diseases. 4th Ed, Churchill Livingstone, New York (1987) pp 983-1003.
19. Dragon DC and Rennie RP: The ecology of anthrax spores: Tough but not invincible. Can Vet J (1995) 36: 295-301.
20. Mallon E and McKee PH: Extraordinary case report: Cutaneous anthrax. Am J Dermatopathol (1997) 19: 79-82.
21. Bell DM, Kozarsky PE and Stephens DS: Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax. Emerg Infect Dis (2002) 8: 222-225.
22. Turnbull PC, Doganay M, Lindeque PM, Aygen B and McLaughlin J: Serology and anthrax in humans, livestock and Etosha National Park wildlife. Epidemiol Infect (1992) 108: 299-313.
23. Sirisanthana T, Nelson KE, Ezzell JW and Abshire TG: Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg (1988) 39: 575-581.
24. Dixon TC, Meselson M, Guillemin J and Hanna PC: Anthrax. N Eng J Med (1999) 341: 815-826.
25. Doganay M and Aydin N: Antimicrobial susceptibility of Bacillus anthracis. Scand J Infect Dis (1991) 23: 333-335.
26. Pile JC, Malone JD, Eitzen EM and Friedlander AM: Anthrax as a potential biological warfare agent. Arch Intern Med (1998) 158: 429-434.
27. Bradaric N and Punda-Polic V: Cutaneous anthrax due to penicillin resistant Bacillus anthracis transmitted by an insect bite. Lancet (1992) 340: 306-307.
28. Lalitha MK and Thomas MK: Penicillin resistance in Bacillus anthracis. Lancet (1997) 349: 1522.
29. Friedlander A, Pittman PR and Parker GW: Anthrax vaccine: Evidence for safety and efficacy against inhalational anthrax. JAMA (1999) 282: 2104-2106.
30. Pittman PR, Gibbs PH, Cannon TL and Friedlander AM: Anthrax vaccine: short-term safety experience in humans. Vaccine (2001) 20: 972-978.